Down 58% from ATH. While Trump just tripled the drone budget to $74B.

The market sold AVAV on Q3 timing noise. Trump's budget just made the underlying thesis bigger than ever.

AVAV traded at $417 in 2024 on the promise of becoming a defense-tech prime. It now trades at $174, down 58%, because the BlueHalo merger created near-term integration pain — a Q3 miss driven by the US government shutdown, a $151M Space-segment goodwill impairment, and gross margin compression from BlueHalo's lower-margin service mix. The market priced this as a structural break. It is not. The funded backlog is at a record $1.1B (up 51% from FY25). YTD bookings are $4.6B. Book-to-bill is 1.6x. And the Trump FY27 budget request triples drone funding while creating an entirely new $54.6B autonomous warfare program. The setup is "right business, wrong moment" — and the wrong moment is ending.

$1.5 trillion total. $74B for drones. And AVAV is the only US-listed pure-play hitting every priority.

To understand AVAV's setup, you have to understand what is about to flow through the Pentagon. The Trump FY27 defense budget request is the largest year-over-year increase in U.S. military spending since World War II — +42% YoY, +$445B over FY26. Inside that headline number sit three line items that map almost perfectly onto AVAV's product portfolio. None of them are speculative. They are in formal budget documents released by the Pentagon comptroller in April 2026.

Line Item 1 — $74B For Drones And Counter-Drones

The FY27 request triples drone spending versus FY26. This is the single largest pure-aligned line item for AVAV. The company produces Switchblade (loitering munitions, used heavily in Ukraine), Puma, Raven, Wasp, and JUMP-20 (small/medium tactical UAS), and the Red Dragon next-gen precision strike system. On the counter-drone side, post-BlueHalo it now produces Titan, TitanSV, LOCUST Laser Weapon System, and Freedom Eagle-1. No other US-listed company has both a major tactical drone franchise AND a major counter-UAS franchise. Kratos does loitering munitions but no counter-UAS. Lockheed and RTX do counter-UAS but not the tactical drone layer. AVAV is the only complete play in a budget that just tripled the category.

Line Item 2 — DAWG Goes From $226M To $54.6B

The Defense Autonomous Warfare Group is the new Pentagon organization replacing the Replicator program — the office responsible for fielding autonomous systems at scale. FY26 budget: $226M. FY27 request: $54.6B. That's a 24,000% increase. DAWG's mission is to identify, integrate, and field the best autonomous platforms from US industrial base partners. AVAV's flagship Switchblade and Puma platforms are exactly the type of attritable autonomous systems DAWG is built to procure at volume. Lessons from Ukraine convinced the Pentagon it needs hundreds of thousands of low-cost autonomous strike systems — and there's only a handful of US companies that can mass-produce them. AVAV's new Utah facility is built specifically to more than double Switchblade capacity.

Line Item 3 — Golden Dome ($17.9B Operationalization)

Trump's "Golden Dome" missile defense system — modeled on Israel's Iron Dome but for the entire continental US — was authorized via Executive Order 14186 and received $25B in initial funding via the FY26 reconciliation bill. The FY27 request adds $17.9B to "operationalize" the system: sensor networks, interceptors, and counter-drone integration. Counter-drone is explicitly part of the Golden Dome architecture (drones are one of the four threat vectors Golden Dome is designed to defeat, alongside cruise missiles, ballistic missiles, and hypersonics). AVAV/BlueHalo's directed energy (LOCUST laser) and counter-UAS (Titan) platforms are the lowest-altitude layer of the Golden Dome stack. If Golden Dome gets built — and the FY27 budget says it is — AVAV gets paid.

The Iran War Wildcard

The US went to war with Iran in February 2026. The FY27 budget request was finalized before the Iran conflict began and does not yet include supplemental funding. Trump is expected to request $80B-$100B in additional supplemental funding for Iran operations. Supplemental defense spending almost always flows disproportionately to munitions consumables (Switchblade rounds are textbook munitions consumables) and counter-drone systems (Iran is the world's largest exporter of attack drones to non-state proxies). Whatever the geopolitics, AVAV's order book benefits from the spending.

17 analyst Buys. $1.1B record backlog. The fundamentals are screaming what the price isn't.

When the operating data and the stock price tell two completely different stories, one of them is wrong. AVAV's funded backlog is at an all-time high. YTD bookings are $4.6B. Book-to-bill is 1.6x. The Army selected the company for Low-Altitude Stalking and Strike Ordnance. The Navy demonstrated the LOCUST laser aboard the USS George H.W. Bush. The Air Force is buying Collaborative Combat Aircraft. The analyst community is unanimous-bullish. And the price went from $417 to $174. The validation stack is overwhelming. The price action is a separate problem.

Tier 1 — Sell-Side & Order Book Validation

Tier 2 — Customer & Program Validation

The actual contract activity tells the story the stock price obscures. Army Low-Altitude Stalking and Strike Ordnance prototype agreement — selected, not bid. Department of War Test Resource Management Center: $43M three-year contract announced May 2026. U.S. Navy LOCUST Laser Weapon System demonstrated aboard the USS George H.W. Bush in October 2025 — first operational at-sea demonstration. Halo_Shield product launch April 2026 (counter-UAS platform). Jump-20 medium UAS in production for multiple US and allied customers. Switchblade 600 in active use by Ukraine since 2022 — operational validation against Russian armored forces. NATO interest in tactical drones at "record levels" per company commentary. Defense buyers do not bet on technology that does not work. Every one of these is a validator.

Tier 3 — The BlueHalo Read-Through

The BlueHalo acquisition closed May 1, 2025 — a $4.1B all-stock deal that doubled AVAV's TAM to $50B+ and added directed energy, space, cyber, and electronic warfare to the portfolio. The Arlington Capital Partners team that built BlueHalo retained significant equity in the combined company under multi-year lockup. That's permanent capital that needs the new AVAV to work. BlueHalo contributed $176.5M of revenue in Q3 alone — a single-quarter contribution larger than some defense-tech IPOs raise in total. The Q3 goodwill impairment was specifically tied to one Space-segment contract (SCAR) being terminated — not a structural failure of the BlueHalo integration. Management is optimistic about a more favorable replacement structure on SCAR. The merger is working; the integration is still messy.

Switchblade. LOCUST. Puma. Titan. Every product is a budget line item.

AeroVironment, Inc. (NASDAQ: AVAV). Founded 1971 by Paul MacCready. Headquartered in Arlington, VA (post-BlueHalo). The original AVAV business was a hand-launched tactical drone manufacturer for the US Department of Defense, known mainly for the Raven, Puma, and Wasp UAS platforms. In 2022 the company moved aggressively into loitering munitions with the Switchblade family — small enough to fit in a soldier's backpack, deployable in minutes, capable of striking armored vehicles. Switchblade became the iconic American weapon system of the Ukraine war. In May 2025, AVAV closed its $4.1B all-stock acquisition of BlueHalo, doubling employee headcount to ~3,750, adding directed-energy weapons, space communications, counter-UAS, and electronic warfare capabilities. The post-merger company has a TAM exceeding $50 billion.

Two Operating Segments

The Five Products Most Aligned With FY27 Spending

The Switchblade Story

Switchblade is the closest thing the modern US military has to a flagship product. It is a small, soldier-portable loitering munition — fired from a tube, flown by the operator via video link, and crashed into a target. The 300 variant targets personnel and light vehicles. The 600 variant targets armored vehicles. The platform was first proven combat-relevant in Ukraine starting 2022, with thousands of units shipped to Ukrainian forces. It is the weapon system that crystallized the Pentagon's new doctrine: cheap, mass-produced, attritable autonomous strike systems are now central to American warfighting. AVAV's new Utah manufacturing facility, announced FY25, more than doubles Switchblade capacity. This is not a side product — Switchblade is the strategic platform that defines AVAV's role in the FY27 budget.

The BlueHalo Capability Stack

BlueHalo brings three high-growth defense franchises that AVAV did not previously have. Directed Energy (LOCUST laser, demonstrated aboard USS George H.W. Bush). Space (BADGER phased arrays, WASP, PANTHER, laser communications, space-qualified payloads). Cyber & Electronic Warfare (Freedom Eagle-1 and adjacent platforms). The strategic logic is that future warfare requires all of these capabilities integrated together — drones operating in contested electromagnetic environments under counter-UAS threat, supported by space comms, all networked. BlueHalo gives AVAV a full-spectrum defense-tech offering — and full-spectrum is what DAWG and Golden Dome are buying.

Q3 miss was timing. The backlog is the truth.

Q3 FY26 Results (Reported March 10)

The Two Things That Caused The Miss

(1) US government shutdown delayed order timing. The Q3 FY26 quarter ended January 31, 2026 — during the federal government funding lapse. Government orders that should have been processed in January slipped to February or later, pushing revenue recognition out of Q3 into Q4 and FY27. This is a calendar issue, not a demand issue. Management explicitly cited the shutdown as the primary cause. (2) BlueHalo Space SCAR contract termination. The SCAR (Strategic and Combatant Command Resilient Communications) contract — a BlueHalo legacy program — was terminated by the customer in January 2026, triggering a stop-work order on BADGER phased array systems and a $151.3M goodwill impairment. Management has signaled "optimism about a more favorable replacement structure" — the requirement still exists, the procurement vehicle is being restructured.

FY26 Guidance (Lowered, Already Priced In)

The Valuation Math

At $174 spot and ~$8.8B market cap, AVAV trades at ~4.5x forward revenue on FY26 mid-point ($1.9B). Defense-tech peers trade meaningfully higher: PLTR ~50x, KTOS ~5x, RKLB ~30x, LDOS ~1.3x. AVAV sits in the middle of the defense-tech band on revenue multiple, but at a deep discount on growth profile — Q3 revenue was +143% YoY. If you believe the backlog converts (and there's no reason to think it won't), the FY27 revenue base is $2.5-3.0B, which gets to a more comfortable 3x EV/Revenue at current cap. The median analyst PT of $305 implies ~$15B market cap, or roughly 5x FY27 sales — exactly what a defense-tech prime with 30%+ growth should trade at.

Analyst Coverage Detail

16 Buy / 2 Hold / 1 Sell. Even the lowest sell-side PT ($235) is +35% from current spot. The setup mathematically favors longs at this price.

Lockheed builds the F-35. AVAV builds the swarm that protects it.

Defense-tech is fragmenting into two distinct categories. The traditional primes — Lockheed (LMT), Raytheon (RTX), Northrop (NOC), General Dynamics (GD) — build platforms: fighter jets, missiles, ships, satellites. Each platform takes 10+ years to develop and costs billions per unit. The new defense-tech challengers — AeroVironment, Kratos, Anduril (private), Shield AI (private), Skydio (private) — build attritable autonomous systems: drones, loitering munitions, counter-UAS, lasers. Each system costs thousands to hundreds of thousands per unit and ships in months. The FY27 budget treats these as separate spend categories — and the new-defense category is growing 3x faster.

The Three Direct Competitive Dynamics

AVAV vs Kratos (KTOS). Both make loitering munitions and unmanned systems. Kratos focuses on jet-powered drones (Valkyrie, Mako) — bigger, more expensive, fewer units. AVAV focuses on smaller tactical systems shipped at volume. Different customer profiles. Both are budget winners. KTOS trades at ~5x EV/Revenue. AVAV at ~4.5x. Comparable valuation, different product mix. AVAV vs Anduril (private). The most-discussed defense-tech competitor. Anduril is private, valued at ~$30B in 2025 funding. Anduril's Roadrunner counter-UAS competes with AVAV's Titan family. Anduril's Bolt loitering munition competes with Switchblade. But Anduril is not yet a major Pentagon revenue line — AVAV is. AVAV has decades of program-of-record positioning Anduril is still building. AVAV vs Palantir (PLTR). Not direct competitors but adjacent. PLTR provides the AI/data layer. AVAV provides the kinetic effectors. PLTR trades at 50x revenue with $185 share price. AVAV trades at 4.5x revenue with $174 share price. The same defense-tech secular story is being priced very differently for the two names.

What Makes AVAV Structurally Different

Three things separate AVAV from every other US-listed defense-tech name:

(1) The complete drone stack. AVAV is the only US-listed name that produces tactical drones (Puma, Raven), loitering munitions (Switchblade), counter-drones (Titan), AND directed-energy counter-drone systems (LOCUST). When DAWG wants to procure an integrated drone-warfare capability, AVAV is the only place to get all four from one vendor.

(2) BlueHalo's directed-energy + space portfolio. Post-merger, AVAV has high-power microwave, laser, and electronic warfare capabilities the pure-play drone names (Kratos) do not. This matters because directed energy is the only economically viable counter to drone swarms — and drones swarms are the threat the entire defense community is most worried about.

(3) Production capacity at scale. The new Utah Switchblade facility more than doubles capacity. Pentagon procurement officials want vendors who can deliver tens of thousands of units, not hundreds. AVAV is one of three or four US companies that can credibly meet that requirement.

The Risk From Anduril

Anduril is the single biggest competitive threat. Founded by Palmer Luckey (Oculus), backed by Founders Fund, ~$30B valuation. Anduril's product line — Bolt loitering munition, Roadrunner C-UAS, Lattice software platform — overlaps significantly with AVAV's portfolio. If Anduril IPOs in the next 12-18 months, it could shift defense-tech multiple expansion to itself. That said, AVAV has $1.1B funded backlog right now. Anduril is still building Pentagon program-of-record relationships AVAV has had for two decades. Public-market investors prefer the company that's already winning contracts.

Right business. Right budget. Wrong moment is ending.

Even the bear case is +35%. The bull case is a triple.

Position Structure

AVAV is a core defense-tech long, not a speculative micro-cap. The risk profile is more like a beaten-down growth name than a moonshot. 3-5% common stock position is appropriate sizing for John's book — same weight class as the existing AI infrastructure and photonics holdings. The right structure is mostly equity with an optional LEAP overlay if you want defined leverage. Options are available (recent IV around 50-60% — elevated but not extreme). Jan 2027 $200C or $220C provide leverage with manageable theta given the 8-month runway through Q1 FY27 earnings + FY27 budget passage. Avoid short-dated options — too much exposure to single-quarter timing noise that the post-merger company is clearly prone to.

The Trade Decomposition

This is a trade with three distinct payoffs that don't require all to land:

(1) Mean reversion. Bear sentiment unwinds. Stock goes from $174 to $235 just by stopping being hated. That's already +35%. Most defense names that traded this far below average analyst target have closed the gap within 12 months.

(2) Catalyst execution. Q4 reports Jun 23 — first chance to validate the "timing not demand" thesis. FY27 budget passage (likely late 2026 / early 2027) is the bigger catalyst. Each successful step adds 20-30%.

(3) Multiple re-rate. If defense-tech multiples normalize toward Palantir-adjacent levels on the back of FY27 budget passage and clear backlog conversion, AVAV gets to $400+. This is the long-tail upside.

Catalyst Calendar

The cheapest defense-tech name. By every framework.

The Three Comps That Matter

AVAV vs KTOS: Direct peer in unmanned systems. Similar valuation (4.5x vs 5x). But KTOS is growing 15% vs AVAV's 143%. AVAV is structurally cheaper on growth-adjusted basis. KTOS has run +85% over the past year while AVAV is -58% from ATH. The mean reversion trade favors AVAV. AVAV vs PLTR: Both AI/defense-tech beneficiaries. PLTR at 50x revenue and $185 share price. AVAV at 4.5x revenue and $174 share price. The market is paying 11x more for PLTR's AI/data narrative than for AVAV's kinetic effector reality. Both win from FY27 budget — PLTR for the AI workflows, AVAV for the weapons. The valuation gap is structurally unjustifiable. AVAV vs LMT: The "old defense vs new defense" trade. LMT at 1.8x revenue with 5% growth. AVAV at 4.5x revenue with 143% growth. Growth-adjusted, AVAV is the cheaper stock — and is positioned for the categories where FY27 budget growth is concentrated (drones, autonomous, DE), not where LMT's franchise sits (jets, ballistic missiles, established primes).

Long AVAV. Core defense-tech position. Stock + LEAPs.

AVAV is the cleanest defense-tech setup on the board right now. The market sold the stock 58% from $417 to $174 on a Q3 miss that management explicitly attributed to government shutdown timing and one BlueHalo legacy contract — and the funded backlog ripped to a record $1.1B at the same time. The Trump FY27 budget request just tripled drone spending to $74B and created a $54.6B autonomous warfare procurement vehicle that maps perfectly onto AVAV's product line. 17 analysts have Buy ratings with a median PT of $305. The June 23 earnings print is the catalyst that resets the narrative. This is not a speculative bet on an unproven business — this is a beaten-down growth name where the operating data and the price action have diverged catastrophically. Sized as a core defense-tech long with optional LEAP overlay. Equity + Jan 2027 calls if you want defined leverage. The bear case is still +35% upside. The bull case is +159%.